📋 Key Information Summary
- Cholesterol emboli syndrome (CES) results from showering of cholesterol crystals from eroded atherosclerotic plaques into small-to-medium arteries, causing downstream ischaemia and an intense inflammatory response.
- Classic triggers: vascular catheterisation, arterial surgery, thrombolysis, and anticoagulation (especially heparin or warfarin initiation/escalation) in patients with severe aortic or iliac atherosclerosis.
- Triad of presentation: livedo reticularis, peripheral eosinophilia, and acute kidney injury (AKI) — though the complete triad is present in fewer than one-third of cases.
- AKI onset: typically delayed 1–8 weeks post-procedure (mean 2–4 weeks), distinguishing CES from contrast-associated AKI which peaks at 48–72 hours.
- Blue-toe syndrome: painful, cyanotic toes with palpable pedal pulses is a hallmark finding of cholesterol microembolisation to the lower limbs.
- Eosinophilia occurs in 60–80 % of cases; hypereosinophilia (>1.5 × 10⁹/L) is a red flag. Eosinophiluria may also be present.
- Hollenhorst plaques on fundoscopy — bright, refractile emboli at arterial bifurcations — are a specific clue when present.
- Diagnosis is primarily clinical in the context of a suggestive trigger; tissue biopsy (skin, kidney) showing biconvex, needle-shaped clefts in arterioles is confirmatory but often unnecessary.
- There is no proven pharmacotherapy to dissolve or clear cholesterol emboli. Management is supportive: cessation of anticoagulation where feasible, aggressive cardiovascular risk-factor modification (statins, antihypertensives, antiplatelet therapy), and renal replacement therapy if required.
- Statins (atorvastatin or rosuvastatin) are strongly recommended — observational data suggest improved survival and renal outcomes through plaque stabilisation and anti-inflammatory effects.
- Mortality is high: in-hospital mortality 16–26 %; 1-year mortality approaches 40–60 % in hospitalised cohorts, driven largely by cardiovascular events and progression to end-stage kidney disease.
- Prevention is paramount — minimise vascular instrumentation, use radial or distal access where possible, and consider atheroembolic risk in patients with known aortic plaques ≥4 mm or mobile atheroma on echocardiography.
- Renal prognosis: approximately 25–30 % of patients require long-term dialysis; partial recovery may occur over months if further embolisation is prevented.
Introduction & Australian Epidemiology
Cholesterol emboli syndrome (CES) — also termed atheroembolic renal disease or cholesterol crystal embolisation — results from the showering of atherosclerotic plaque material into renal and other end-organ vessels, most commonly following vascular procedures, arterial surgery, thrombolysis, or anticoagulation therapy.
The disorder was first described by Flory in 1945 at autopsy in patients with severe aortic atherosclerosis. With the proliferation of endovascular procedures, cardiac catheterisation, and percutaneous coronary intervention (PCI), clinically apparent CES has become an increasingly recognised cause of acute kidney injury (AKI) and multisystem organ dysfunction.
Australian Context
Australia's ageing population and high burden of cardiovascular disease place many older Australians at risk. Approximately 180,000 coronary angiography procedures are performed annually in Australia, and a further 25,000–30,000 peripheral vascular interventions add to the population at risk. The true incidence of clinically apparent CES is estimated at 0.5–2 % of patients undergoing catheter-based vascular procedures, though subclinical embolisation (detected on renal biopsy) may occur in up to 25–30 % of post-mortem studies in patients with severe aortic atherosclerosis.
CES disproportionately affects men (male:female ratio approximately 3–4:1), typically presenting in the 6th–8th decade of life. Patients with known abdominal aortic aneurysm, diffuse iliofemoral disease, prior aortic valve replacement, or mobile aortic arch atheroma on transoesophageal echocardiography (TOE) are at highest risk.
Data from the Australian Institute of Health and Welfare (AIHW) and the ANZDATA Registry indicate that atheroembolic disease accounts for a small but significant proportion of hospital-acquired AKI, particularly in tertiary centres performing high volumes of endovascular work. Importantly, CES is thought to be substantially underdiagnosed, as the clinical features overlap with contrast-associated AKI, vasculitis, and nephrosclerosis.
Diagnostic pitfall: CES is frequently misdiagnosed as contrast-associated AKI, vasculitis (particularly ANCA-associated), or hypertensive nephrosclerosis. Consider CES whenever AKI follows a vascular procedure and onset is delayed beyond 72 hours, particularly if accompanied by livedo, eosinophilia, or blue-toe syndrome.
Pathophysiology & Triggers
Mechanism of Embolisation
Cholesterol emboli arise from the rupture or erosion of atherosclerotic plaques, most commonly in the abdominal aorta, iliac arteries, or aortic arch. When the fibrous cap of a plaque is disrupted — by mechanical trauma (catheter passage, cross-clamping), thrombolytic dissolution of protective thrombus, or changes in haemodynamic shear stress — cholesterol crystals, necrotic lipid debris, and platelet-fibrin aggregates are released into the arterial circulation.
These emboli are typically 100–200 µm in diameter and lodge in small arterioles of the kidneys, skin, gastrointestinal tract, retina, brain, and skeletal muscle. Unlike thromboemboli, cholesterol crystals are rigid and cannot be lysed by fibrinolytic agents. Once impacted, they provoke a biphasic vascular response:
- Acute phase (hours–days): mechanical obstruction of arteriolar lumen, platelet adhesion, and endothelial damage.
- Subacute phase (days–weeks): intense intimal proliferation, giant-cell foreign-body reaction around the biconvex needle-shaped cholesterol clefts, and fibrosis — leading to progressive arteriolar occlusion and organ ischaemia.
This delayed inflammatory response explains the characteristic latency of 1–8 weeks between the embolic event and peak clinical manifestations, particularly progressive renal impairment.
Precipitating Triggers
| Trigger Category | Specific Triggers | Relative Risk |
|---|---|---|
| Endovascular procedures | Coronary angiography, peripheral angioplasty, aortic stenting, endovascular aneurysm repair (EVAR), intra-aortic balloon pump insertion | High — most common identifiable cause |
| Vascular surgery | Aortic cross-clamping, aortic valve replacement, aortobifemoral bypass, carotid endarterectomy | High — 1–3 % post-aortic surgery |
| Anticoagulation | Heparin (UFH or LMWH) initiation, warfarin initiation or dose escalation, DOACs (less commonly reported) | Moderate — may dissolve protective mural thrombus |
| Thrombolytic therapy | IV alteplase for STEMI, catheter-directed thrombolysis for PE or limb ischaemia | Moderate |
| Spontaneous | No identifiable iatrogenic trigger — may occur with plaque progression, severe hypertension, or haemodynamic stress | Low (but increasingly recognised) |
Anatomical Risk Factors
The following anatomical features significantly increase the risk of CES:
- Aortic plaque thickness ≥ 4 mm (OR 3.2) or mobile atheroma on TOE
- Abdominal aortic aneurysm with intraluminal thrombus
- Diffuse aortoiliac occlusive disease
- Porcelain aorta (heavily calcified ascending aorta)
- Previous prosthetic aortic valve — atheromatous degeneration at the annular site
Anticoagulation paradox: Anticoagulants are frequently used in patients with vascular disease — precisely the population most susceptible to CES. Anticoagulation may dissolve protective mural thrombus covering an atherosclerotic plaque, exposing and releasing cholesterol debris. This "anticoagulant-associated CES" has been reported with heparin, warfarin, and less commonly with DOACs.
Clinical Features (Livedo, Eosinophilia, AKI)
CES is a multisystem disorder. Cholesterol crystals embolise to virtually any organ, producing a protean clinical picture. The onset is typically delayed 1–14 days after the embolic insult, with progressive worsening over 2–8 weeks as the inflammatory response evolves.
Classic Triad
The textbook triad — present simultaneously in approximately 25–30 % of patients — comprises:
- Livedo reticularis — a violaceous, net-like mottling of the skin, typically affecting the lower limbs, buttocks, and trunk. Results from arteriolar occlusion in the dermal and subdermal vascular plexus. May progress to skin necrosis or gangrene.
- Eosinophilia — peripheral eosinophil count >0.5 × 10⁹/L, present in 60–80 % of cases. Hypereosinophilia (>1.5 × 10⁹/L) occurs in 15–25 %. May be transient and missed if the full blood count is not monitored serially. Eosinophiluria (Wright stain or Hansel stain of urine sediment) may also be detected.
- Acute kidney injury (AKI) — typically non-oliguric, progressive over days to weeks, with bland urinary sediment (few casts, minimal proteinuria). Bilateral renal embolisation is the rule. Creatinine may rise gradually over weeks before plateauing.
Peripheral Vascular Manifestations
- Blue-toe syndrome: sudden onset of painful, cyanotic, often gangrenous toes with preserved pedal pulses — the hallmark of digital embolisation. Present in 35–50 % of CES patients.
- Livedo reticularis / racemosa: as above; may be associated with tender subcutaneous nodules.
- Peripheral gangrene: in severe cases; may necessitate amputation.
- Myalgia: diffuse limb pain from skeletal muscle ischaemia.
Renal Manifestations
- AKI: the most common presentation prompting investigation. Typically non-oliguric; urine microscopy shows bland sediment, mild proteinuria (<1 g/day), and occasional eosinophiluria.
- Hypertension: new or worsened hypertension due to renin-mediated responses from ischaemic nephrons (renovascular-type mechanism).
- Haematuria: may be present but is typically mild; gross haematuria is uncommon.
- Flank pain: occasionally reported due to renal infarction.
Systemic & Extrarenal Features
| Organ System | Features | Frequency |
|---|---|---|
| Ocular | Hollenhorst plaques (refractile emboli at retinal arteriolar bifurcations); visual field defects; amaurosis fugax | 10–25 % |
| Gastrointestinal | Abdominal pain, GI bleeding, nausea/vomiting, pancreatitis, bowel infarction | 15–30 % |
| Neurological | Transient ischaemic attack (TIA), stroke, confusion, spinal cord ischaemia | 10–20 % |
| Cardiac | Myocardial infarction (Type 2), pericarditis, new heart failure | 5–10 % |
| Constitutional | Fever, weight loss, malaise, myalgia, anorexia | 40–60 % |
Temporal Patterns
Day 0–3
Embolic event (procedure, anticoagulation initiation). Patient may be asymptomatic initially.
Day 3–14
Early clinical features emerge: livedo reticularis, blue toes, fever, eosinophilia, rising creatinine. Constitutional symptoms (malaise, myalgia).
Week 2–8
Progressive AKI, worsening skin lesions, systemic complications (GI, CNS, cardiac). Peak clinical severity.
Week 8–16+
Plateau or slow recovery phase. Renal function stabilises (may require long-term dialysis). Skin lesions may improve or progress to gangrene.
Investigations & Diagnosis
Diagnosis of CES is primarily clinical, based on the temporal association with a known trigger, compatible clinical features (livedo, eosinophilia, AKI, blue-toe syndrome), and exclusion of alternative diagnoses. There is no single pathognomonic test, though tissue biopsy provides definitive confirmation.
Laboratory Investigations
ESSENTIAL
Full Blood Count (FBC) with differential
Eosinophilia (>0.5 × 10⁹/L) in 60–80 %. Serial counts recommended — eosinophilia may be transient. ESR and CRP typically elevated (non-specific).
ESSENTIAL
Serum Creatinine & eGFR
Progressive rise over days to weeks post-trigger. Typically non-oliguric. Distinguish from contrast-associated AKI (onset 48–72 h, peaks day 3–5).
ESSENTIAL
Urinalysis & Urine Microscopy
Bland sediment with few casts. Mild proteinuria (<1 g/day). Eosinophiluria on Wright or Hansel stain is supportive but has limited sensitivity (~30–40 %). Culture to exclude infection.
AVAILABLE
ANCA, ANA, dsDNA, complement levels
Essential to exclude ANCA-associated vasculitis, lupus nephritis, and other immune-mediated glomerulonephritides. Typically normal in CES.
AVAILABLE
LDH, haptoglobin, blood film
To exclude thrombotic microangiopathy (TMA). LDH may be mildly elevated in CES from tissue ischaemia but haptoglobin is typically normal.
AVAILABLE
Blood cultures
If fever is present — to exclude infective endocarditis with septic emboli.
Imaging
AVAILABLE
CT Abdomen with contrast
May show wedge-shaped renal infarcts, aortic atheroma, or intraluminal thrombus. Non-contrast CT has limited sensitivity. Avoid further iodinated contrast if AKI is established (discuss risk-benefit).
AVAILABLE
Duplex Ultrasound of Renal Arteries
May demonstrate reduced cortical perfusion but is insensitive for arteriolar-level embolisation. Useful to exclude renovascular occlusion.
AVAILABLE
Echocardiography (TOE preferred)
To identify mobile aortic arch atheroma, prosthetic valve dysfunction, or intracardiac thrombus — potential embolic sources. TOE is superior to TTE for aortic plaque detection.
AVAILABLE
Ophthalmoscopy / Retinal Photography
Hollenhorst plaques — bright, refractile, orange-yellow emboli at arteriolar bifurcations — are highly suggestive of atheroembolic disease. Present in 10–25 %.
Tissue Biopsy
Biopsy of affected tissue is the gold standard for diagnosis. Findings on histology:
- Pathognomonic finding: biconvex, needle-shaped cholesterol clefts within arteriolar lumina (visible on H&E as empty, slit-like spaces — cholesterol is dissolved during processing).
- Associated features: intimal proliferation, giant-cell foreign-body reaction, fibrin thrombi, and arteriolar fibrosis.
- Skin biopsy: most accessible site — punch biopsy of livedo lesions or blue toes carries high diagnostic yield (~75 %) and low morbidity.
- Renal biopsy: higher diagnostic yield but greater procedural risk in anticoagulated or azotaemic patients. Reserve for diagnostic uncertainty when skin biopsy is non-diagnostic.
- MBS item: Skin biopsy (MBS item 30071/30072); renal biopsy by nephrologist (discuss with renal unit — MBS item applies).
Renal biopsy risk: Renal biopsy in the setting of uncontrolled hypertension, AKI, or coagulopathy carries increased bleeding risk. Consider skin biopsy first. If renal biopsy is needed, correct coagulopathy and ensure blood pressure is controlled (<160/90 mmHg).
Diagnostic Criteria
No universally accepted diagnostic criteria exist, but the following framework is widely used:
1
Temporal trigger
Vascular procedure, anticoagulation initiation, or thrombolysis within the preceding 1–12 weeks.
2
Compatible clinical features
≥2 of: livedo reticularis, blue-toe syndrome, eosinophilia, AKI with bland urine, Hollenhorst plaques.
3
Exclusion of mimics
Vasculitis (ANCA/ANA), TMA (haptoglobin, blood film), infective endocarditis (blood cultures), contrast nephropathy (timeline), renovascular thrombosis.
4
Histological confirmation (if obtained)
Cholesterol clefts in arterioles on skin or renal biopsy — definitive.
Management & Prognosis
No proven definitive therapy exists. Cholesterol crystals are rigid and cannot be dissolved by anticoagulants, thrombolytics, or antiplatelet agents. Management is entirely supportive, focused on preventing further embolisation, controlling complications, and renal replacement therapy if needed.
Immediate Management
1. Cessation or Avoidance of Trigger
- Anticoagulation: if CES is triggered by anticoagulation initiation/escalation, discontinue if clinically safe. This is the single most important intervention. The decision must balance thrombotic risk (e.g., mechanical heart valve, recent DVT/PE) against the risk of ongoing embolisation.
- Avoid further vascular instrumentation: postpone elective catheterisation and surgery.
- Thrombolysis: discontinue if suspected.
2. Supportive Care
- Fluid and electrolyte management; avoid nephrotoxins (NSAIDs, iodinated contrast, aminoglycosides).
- Renal replacement therapy (haemodialysis or peritoneal dialysis) if indicated by standard criteria (refractory hyperkalaemia, acidosis, volume overload, uraemic symptoms).
- Wound care for skin lesions and gangrenous toes; podiatric and vascular surgery input as needed.
- Adequate analgesia for limb ischaemia and skin ulceration.
Pharmacological Management
No randomised controlled trials have demonstrated efficacy for any specific therapy in CES. The following are recommended based on observational data, pathophysiological rationale, and expert consensus:
Atorvastatin
Lipitor® · Generic · HMG-CoA reductase inhibitor
Adult dose
40–80 mg PO daily
Rationale
Plaque stabilisation, anti-inflammatory effects, improved endothelial function. Observational data suggest reduced mortality and slower renal decline.
Renal adjustment
No adjustment required
PBS status
✔ PBS General Benefit
Rosuvastatin
Crestor® · Generic · HMG-CoA reductase inhibitor
Adult dose
20–40 mg PO daily
Rationale
Alternative to atorvastatin. Potent LDL-lowering and anti-inflammatory properties.
Renal adjustment
Start 5 mg if eGFR <30 mL/min/1.73 m²; max 10 mg daily
PBS status
✔ PBS General Benefit
Aspirin
Aspro Clear® · Generic · Antiplatelet
Adult dose
100 mg PO daily
Rationale
Prevents platelet aggregation on ulcerated plaques. Standard secondary prevention in atherosclerotic disease. Resume once acute CES episode is controlled if ongoing thrombotic risk.
Renal adjustment
No adjustment required
PBS status
✔ PBS General Benefit
Clopidogrel
Plavix® · Generic · P2Y12 inhibitor
Adult dose
75 mg PO daily
Rationale
Consider as alternative or in combination with aspirin (DAPT) if strong cardiovascular indication and anticoagulation has been safely withdrawn.
Renal adjustment
No adjustment required
PBS status
✔ PBS General Benefit
Amlodipine
Norvasc® · Generic · Calcium channel blocker
Adult dose
5–10 mg PO daily
Rationale
Antihypertensive — avoid ACEI/ARB initially if renal artery embolisation suspected (risk of further GFR decline from efferent arteriolar vasodilation). CCB is preferred early.
Renal adjustment
No adjustment required
PBS status
✔ PBS General Benefit
ACEI/ARB caution: Avoid angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) in the acute phase of CES. Bilateral renal embolisation may produce a renovascular-type physiology, and ACEI/ARB can precipitate rapid deterioration in GFR. Use calcium channel blockers or beta-blockers for blood pressure control initially. ACEI/ARB may be cautiously introduced later if renal function has stabilised and renovascular cause is excluded.
Therapies NOT Recommended
| Therapy | Rationale Against Use |
|---|---|
| Anticoagulation (heparin, warfarin) | May worsen embolisation by dissolving protective mural thrombus; no evidence of benefit. Avoid unless compelling thrombotic indication (e.g., mechanical heart valve). |
| Thrombolysis (alteplase, tenecteplase) | Cannot dissolve cholesterol crystals. Carries bleeding risk. No role in CES. |
| Corticosteroids | Often empirically given for eosinophilia. No proven benefit in CES; eosinophilia typically self-resolves. May mask concurrent infection. |
| Prostacyclin (iloprost, epoprostenol) | Some small case series suggest benefit; evidence insufficient for routine recommendation. Available on Authority PBS for other indications only. |
| Surgical embolectomy | Not feasible — emboli are diffuse and at the arteriolar level. Aortic endarterectomy carries further embolic risk. |
Long-Term Cardiovascular Risk Management
All patients with CES should receive aggressive secondary cardiovascular prevention:
- Statin therapy: high-intensity (atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily) — lifelong.
- Antiplatelet therapy: aspirin 100 mg daily or clopidogrel 75 mg daily — lifelong (unless contraindicated).
- Blood pressure control: target <130/80 mmHg (or per individual renal tolerance).
- Smoking cessation: absolute priority — refer to Quitline (13 7848) and consider pharmacotherapy (varenicline PBS-listed).
- Diabetes optimisation: HbA1c target ≤53 mmol/mol (7.0 %) or individualised.
- Exercise and dietary counselling: cardiac rehabilitation programme if appropriate.
- Weight management: BMI <30 kg/m²; waist circumference targets.
Prognosis
Favourable
Limited Embolisation
Isolated skin findings, mild AKI (Stage 1–2), early trigger recognition. Statin and antiplatelet therapy commenced promptly.
Outcome: Renal function may improve over 3–6 months. 1-year survival ~80 %.
Guarded
Multisystem Involvement
AKI Stage 3 (but not dialysis-dependent), GI symptoms, livedo with skin necrosis, delayed diagnosis.
Outcome: Partial renal recovery likely. 1-year survival ~50–60 %. Requires long-term nephrology follow-up.
Poor
Dialysis-Dependent / Multisystem Failure
Dialysis-dependent AKI, bowel ischaemia, stroke, gangrene requiring amputation, ongoing embolisation.
Outcome: In-hospital mortality 16–26 %. 1-year mortality 40–60 %. ~25–30 % remain dialysis-dependent.
Key prognostic factors: (1) Extent of aortic atherosclerosis — diffuse disease predicts worse outcomes. (2) Number of organs involved — multisystem embolisation carries mortality >75 %. (3) Severity and trajectory of AKI — dialysis dependence is the strongest predictor of poor renal outcome. (4) Time to diagnosis — delayed recognition allows ongoing embolisation.
Special Populations
Elderly Patients
Highest-risk demographic
CES predominantly affects patients aged >65 years with extensive atherosclerosis. Renal function is often compromised at baseline, making AKI more severe. Dose-adjust medications (especially rosuvastatin, renally-cleared agents). Falls risk with hypotension.
Frailty assessment
Consider goals of care — dialysis initiation in frail elderly with diffuse atheroembolic disease has a very high mortality. Shared decision-making with patient and family is essential.
Renal Impairment
Pre-existing CKD
Patients with CKD Stage 3–5 are at higher risk of severe AKI from CES. Avoid nephrotoxins. Monitor for hyperkalaemia and volume overload. Renal dose-adjust rosuvastatin; atorvastatin requires no adjustment.
Dialysis-dependent
If long-term dialysis is required, haemodialysis or peritoneal dialysis are both suitable. AV fistula creation carries further embolic risk — consider peritoneal dialysis catheter or tunnelled haemodialysis catheter as bridge.
Pregnancy
Extremely rare in pregnancy
CES is predominantly a disease of elderly atherosclerotic patients. In the rare young patient with CES, statins are contraindicated in pregnancy (FDA Category X). Aspirin at low dose (100 mg) is acceptable for pre-eclampsia prophylaxis but risk-benefit must be discussed. Multidisciplinary team involvement essential.
Paediatric Patients
Not applicable
CES is essentially unreported in paediatric practice. Paediatric AKI has different aetiologies. If encountered (e.g., cholesterol crystal deposition in paediatric nephrotic syndrome), consult tertiary paediatric nephrology.
Immunocompromised Patients
Diagnostic challenge
Eosinophilia — a key diagnostic clue — may be absent in patients on corticosteroids, post-transplant immunosuppression, or with HIV-associated eosinopenia. Maintain a high index of clinical suspicion. Skin biopsy is particularly valuable in this group. Infection must always be excluded.
Hepatic Impairment
Statins in liver disease
Atorvastatin and rosuvastatin are hepatically metabolised. Avoid in active liver disease or unexplained persistent transaminase elevation >3× ULN. Monitor LFTs at baseline, 6 weeks, and 3-monthly thereafter. Dose-adjust if Child-Pugh B/C — consult hepatology/pharmacy.
Aboriginal and Torres Strait Islander Health Considerations
Aboriginal and Torres Strait Islander Health
📚 References
- 1. Scolari F, Ravani P. Atheroembolic renal disease. Lancet. 2010;375(9726):1650–1660.
- 2. Belenfant M, Meyrier A, Jacquot C. Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis. 1999;33(5):840–850.
- 3. Scolari F, Ravani P, Pola A, et al. Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study. J Am Soc Nephrol. 2003;14(6):1584–1590.
- 4. Modi KS, Rao VK. Atheroembolic renal disease. J Am Soc Nephrol. 2001;12(8):1781–1787.
- 5. Saric M, Kronzon I. Aortic atherosclerosis and embolic events. Curr Cardiol Rep. 2012;14(3):342–349.
- 6. Kronzon I, Saric M. Cholesterol embolization syndrome. Circulation. 2010;122(6):631–641.
- 7. Tayal R, Pollono E, Pahuja M, et al. Cholesterol embolization syndrome: a review of the current literature. J Invasive Cardiol. 2021;33(7):E530–E541.
- 8. The Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 10th edn. East Melbourne: RACGP; 2024.
- 9. Australian Institute of Health and Welfare (AIHW). Cardiovascular disease in Aboriginal and Torres Strait Islander people. Canberra: AIHW; 2023.
- 10. ANZDATA Registry. 46th Annual Report 2023. Adelaide: Australia and New Zealand Dialysis and Transplant Registry; 2023.
- 11. Heart Foundation of Australia. Absolute cardiovascular disease risk management. Melbourne: NHF; 2023.
- 12. RHDAustralia (ACIL Allen Consulting). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd edn. Darwin: RHDAustralia; 2020.
- 13. Nair N, O'Driscoll J, Bhagat K. Cholesterol embolisation — an underdiagnosed cause of multisystem disease. BMJ. 2019;364:l586.
- 14. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd edn. Sydney: ACSQHC; 2021.